Exencial Wealth Advisors LLC Sells 8,694 Shares of Pfizer Inc. (NYSE:PFE)

Exencial Wealth Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 95,956 shares of the biopharmaceutical company’s stock after selling 8,694 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Pfizer were worth $2,763,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Burney Co. grew its holdings in shares of Pfizer by 2.7% in the third quarter. Burney Co. now owns 69,284 shares of the biopharmaceutical company’s stock worth $2,298,000 after purchasing an additional 1,816 shares during the last quarter. Pathstone Family Office LLC increased its position in shares of Pfizer by 139.0% during the third quarter. Pathstone Family Office LLC now owns 453,685 shares of the biopharmaceutical company’s stock worth $15,195,000 after acquiring an additional 263,885 shares during the period. Obermeyer Wood Investment Counsel Lllp raised its stake in shares of Pfizer by 1.8% during the third quarter. Obermeyer Wood Investment Counsel Lllp now owns 39,732 shares of the biopharmaceutical company’s stock valued at $1,318,000 after acquiring an additional 715 shares in the last quarter. Shepherd Financial Partners LLC boosted its holdings in shares of Pfizer by 6.0% in the third quarter. Shepherd Financial Partners LLC now owns 76,019 shares of the biopharmaceutical company’s stock valued at $2,521,000 after purchasing an additional 4,275 shares during the period. Finally, Chase Investment Counsel Corp grew its stake in Pfizer by 199.6% in the third quarter. Chase Investment Counsel Corp now owns 34,619 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 23,062 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.7 %

NYSE:PFE opened at $28.59 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company’s 50 day moving average is $27.50 and its two-hundred day moving average is $27.88.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm earned $1.23 EPS. The firm’s revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.88%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

Several brokerages have weighed in on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $35.86.

Read Our Latest Analysis on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.